icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
wsb9M5bqW0XR07Ab
Listen
